Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
editorial
. 1991 Jul;64(1):7–9. doi: 10.1038/bjc.1991.230

Chemotherapy for metastatic soft tissue sarcomas--another full circle?

V H Bramwell
PMCID: PMC1977315  PMID: 1854630

Full text

PDF
7

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K. H., Ryan L., Elias A., Sherman D., Grier H. E. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989 Jan;7(1):126–131. doi: 10.1200/JCO.1989.7.1.126. [DOI] [PubMed] [Google Scholar]
  2. Baker L. H., Frank J., Fine G., Balcerzak S. P., Stephens R. L., Stuckey W. J., Rivkin S., Saiki J., Ward J. H. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613). J Clin Oncol. 1987 Jun;5(6):851–861. doi: 10.1200/JCO.1987.5.6.851. [DOI] [PubMed] [Google Scholar]
  3. Benjamin R. S. Grade 3 nausea, vomiting, and myelosuppression or progressive, metastatic sarcoma? J Clin Oncol. 1987 Jun;5(6):833–835. doi: 10.1200/JCO.1987.5.6.833. [DOI] [PubMed] [Google Scholar]
  4. Bodey G. P., Rodriguez V., Murphy W. K., Burgess A., Benjamin R. S. Protected environment - prophylactic antibiotic program for malignant sarcomas: randomized trial during remission induction chemotherapy. Cancer. 1981 May 15;47(10):2422–2429. doi: 10.1002/1097-0142(19810515)47:10<2422::aid-cncr2820471017>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  5. Borden E. C., Amato D. A., Rosenbaum C., Enterline H. T., Shiraki M. J., Creech R. H., Lerner H. J., Carbone P. P. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987 Jun;5(6):840–850. doi: 10.1200/JCO.1987.5.6.840. [DOI] [PubMed] [Google Scholar]
  6. Brade W. P., Herdrich K., Varini M. Ifosfamide--pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985 Mar;12(1):1–47. doi: 10.1016/0305-7372(85)90011-8. [DOI] [PubMed] [Google Scholar]
  7. Bramwell V. H. Current perspectives in the management of soft-tissue sarcoma. The role of chemotherapy in multimodality therapy. Can J Surg. 1988 Nov;31(6):390–396. [PubMed] [Google Scholar]
  8. Bramwell V. H., Mouridsen H. T., Mulder J. H., Somers R., Van Oosterom A. T., Santoro A., Thomas D., Sylvester R., Markham D. Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study. Eur J Cancer Clin Oncol. 1983 Aug;19(8):1097–1104. doi: 10.1016/0277-5379(83)90034-2. [DOI] [PubMed] [Google Scholar]
  9. Bramwell V. H., Mouridsen H. T., Santoro A., Blackledge G., Somers R., Verwey J., Dombernowsky P., Onsrud M., Thomas D., Sylvester R. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 1987 Mar;23(3):311–321. doi: 10.1016/0277-5379(87)90075-7. [DOI] [PubMed] [Google Scholar]
  10. Bryant B. M., Wiltshaw E. Results of the Royal Marsden Hospital second soft tissue sarcoma schedule (STS II) chemotherapy regimen in the management of advanced sarcoma. Cancer Treat Rep. 1980 Apr-May;64(4-5):689–692. [PubMed] [Google Scholar]
  11. Bui N. B., Chauvergne J., Hocke C., Durand M., Brunet R., Coindre J. M. Analysis of a series of sixty soft tissue sarcomas in adults treated with a cyclophosphamide-vincristine-adriamycin-dacarbazine (CYVADIC) combination. Cancer Chemother Pharmacol. 1985;15(1):82–85. doi: 10.1007/BF00257301. [DOI] [PubMed] [Google Scholar]
  12. Cantwell B. M., Carmichael J., Ghani S., Harris A. L. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma. Cancer Chemother Pharmacol. 1988;21(1):49–52. doi: 10.1007/BF00262738. [DOI] [PubMed] [Google Scholar]
  13. Chan H. S., Thorner P. S., Haddad G., Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol. 1990 Apr;8(4):689–704. doi: 10.1200/JCO.1990.8.4.689. [DOI] [PubMed] [Google Scholar]
  14. Cormier W. J., Hahn R. G., Edmonson J. H., Eagan R. T. Phase II study in advanced sarcoma: randomized trial of pyrazofurin versus combination cyclophosphamide, doxorubicin, and cis-dichlorodiammineplatinum(II) (CAP). Cancer Treat Rep. 1980 Apr-May;64(4-5):655–658. [PubMed] [Google Scholar]
  15. Edmonson J. H., Hahn R. G., Schutt A. J., Bisel H. F., Ingle J. N. Cyclophosphamide, doxorubicin, and cisplatin combined in the treatment of advanced sarcomas. Med Pediatr Oncol. 1983;11(5):319–321. doi: 10.1002/mpo.2950110504. [DOI] [PubMed] [Google Scholar]
  16. Edmonson J. H., Long H. J., Richardson R. L., Creagan E. T., Green S. J. Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. Cancer Chemother Pharmacol. 1985;15(2):181–182. doi: 10.1007/BF00257535. [DOI] [PubMed] [Google Scholar]
  17. Elias A., Ryan L., Sulkes A., Collins J., Aisner J., Antman K. H. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989 Sep;7(9):1208–1216. doi: 10.1200/JCO.1989.7.9.1208. [DOI] [PubMed] [Google Scholar]
  18. Fahrer C., Brachmann R., von der Helm K. Expression of c-sis and other cellular proto-oncogenes in human sarcoma cell lines and biopsies. Int J Cancer. 1989 Oct 15;44(4):652–657. doi: 10.1002/ijc.2910440416. [DOI] [PubMed] [Google Scholar]
  19. Gerlach J. H., Bell D. R., Karakousis C., Slocum H. K., Kartner N., Rustum Y. M., Ling V., Baker R. M. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol. 1987 Sep;5(9):1452–1460. doi: 10.1200/JCO.1987.5.9.1452. [DOI] [PubMed] [Google Scholar]
  20. Gottlieb J. A., Benjamin R. S., Baker L. H., O'Bryan R. M., Sinkovics J. G., Hoogstraten B., Quagliana J. M., Rivkin S. E., Bodey G. P., Sr, Rodriguez V. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976 Feb;60(2):199–203. [PubMed] [Google Scholar]
  21. Hilgard P., Herdrich K., Brade W. Ifosfamide--current aspects and perspectives. Cancer Treat Rev. 1983 Sep;10 (Suppl A):183–192. doi: 10.1016/s0305-7372(83)80027-9. [DOI] [PubMed] [Google Scholar]
  22. Karakousis C. P., Dal Cin P., Turc-Carel C., Limon J., Sandberg A. A. Chromosomal changes in soft-tissue sarcomas. A new diagnostic parameter. Arch Surg. 1987 Nov;122(11):1257–1260. doi: 10.1001/archsurg.1987.01400230043007. [DOI] [PubMed] [Google Scholar]
  23. Karakousis C. P., Rao U., Park H. C. Combination chemotherapy (CYVADIC) in metastatic soft tissue sarcomas. Eur J Cancer Clin Oncol. 1982 Jan;18(1):33–36. doi: 10.1016/0277-5379(82)90021-9. [DOI] [PubMed] [Google Scholar]
  24. Lynch G., Magill G. B., Sordillo P., Golbey R. B. Combination chemotherapy of advanced sarcomas in adults with "CYOMAD" (S7). Cancer. 1982 Nov 1;50(9):1724–1727. doi: 10.1002/1097-0142(19821101)50:9<1724::aid-cncr2820500912>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  25. Mansi J. L., Fisher C., Wiltshaw E., MacMillan S., King M., Stuart-Harris R. A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. Eur J Cancer Clin Oncol. 1988 Sep;24(9):1439–1443. doi: 10.1016/0277-5379(88)90334-3. [DOI] [PubMed] [Google Scholar]
  26. Mouridsen H. T., Bastholt L., Somers R., Santoro A., Bramwell V., Mulder J. H., van Oosterom A. T., Buesa J., Pinedo H. M., Thomas D. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1477–1483. doi: 10.1016/0277-5379(87)90089-7. [DOI] [PubMed] [Google Scholar]
  27. O'Bryan R. M., Luce J. K., Talley R. W., Gottlieb J. A., Baker L. H., Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer. 1973 Jul;32(1):1–8. doi: 10.1002/1097-0142(197307)32:1<1::aid-cncr2820320101>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  28. Pfeffer M. R., Sulkes A., Biran S. Cyclophosphamide, adriamycin, DTIC and vincristine with methotrexate in the treatment of advanced soft tissue sarcomas. Isr J Med Sci. 1988 Sep-Oct;24(9-10):599–603. [PubMed] [Google Scholar]
  29. Pinedo H. M., Bramwell V. H., Mouridsen H. T., Somers R., Vendrik C. P., Santoro A., Buesa J., Wagener T., van Oosterom A. T., van Unnik J. A. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer. 1984 May 1;53(9):1825–1832. doi: 10.1002/1097-0142(19840501)53:9<1825::aid-cncr2820530904>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  30. Presgrave P., Woods R. L., Tattersall M. H., Coates A. S., Levi J. A., Fox R. M., Hedley D. Chemotherapy of adult soft tissue sarcoma with combination of doxorubicin and methotrexate. Cancer Treat Rep. 1987 Nov;71(11):1087–1088. [PubMed] [Google Scholar]
  31. Schoenfeld D. A., Rosenbaum C., Horton J., Wolter J. M., Falkson G., DeConti R. C. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 1982 Dec 15;50(12):2757–2762. doi: 10.1002/1097-0142(19821215)50:12<2757::aid-cncr2820501211>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  32. Schütte J., Mouridsen H. T., Stewart W., Santoro A., van Oosterom A. T., Somers R., Blackledge G., Verweij J., Dombernowsky P., Thomas D. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 1990;26(5):558–561. doi: 10.1016/0277-5379(90)90075-5. [DOI] [PubMed] [Google Scholar]
  33. Subramanian S., Wiltshaw E. Chemotherapy of sarcoma. A comparison of three regimens. Lancet. 1978 Apr 1;1(8066):683–686. doi: 10.1016/s0140-6736(78)90798-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES